D3-GHR Polymorphism and Turner Syndrome

D3-Growth Hormone Receptor Polymorphism and Total Effect of Recombinant Human Growth Hormone on Growth in Girls With Turner Syndrome

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00443144

Enrollment

Unknown

Registered

2007-03-05

Start date

2005-05-31

Completion date

2007-05-31

Last updated

2015-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Short Stature, Turner Syndrome

Keywords

growth hormone receptor polymorphism, pharmacogenomics, growth promoting therapy

Brief summary

The protein polymorphism of the growth hormone receptor characterized by the genomic deletion of exon 3 has been linked to the magnitude of the first-year-growth response to growth hormone (GH) in girls with Turner syndrome. Objective: to study the long-term effect of GH therapy in Turner syndrome in correlation to this GHR polymorphism in a mainly retrospective design (chart-review).

Interventions

DRUGrecombinant human growth hormone

Eligibility

Sex/Gender

FEMALE

Age

38 Months to 14 Years

Inclusion criteria

* Turner syndrome defined by a structural aberration or lack of the X chromosome. * Growth velocity less than 2 cm/year at the time of final analysis (= final height).

Exclusion criteria

* Age \<3.5 or \>14 years at start of GH therapy, * GH peak serum levels \< 8 ng/ml in two independent tests, * Thelarche at start or during the first year of treatment, * Oxandrolone therapy for any time and a duration of GH therapy less than 2 years.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026